Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating
Amneal Pharmaceuticals (AMRX) Receives a Buy From Piper Sandler
Amneal Pharmaceuticals Analyst Ratings
Truist Securities Reiterates Buy on Amneal Pharmaceuticals, Raises Price Target to $9
Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Amneal Pharmaceuticals (AMRX)
Analysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)
Amneal Pharmaceuticals Analyst Ratings
Amneal Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Novartis (NVS), Quanterix (QTRX) and Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals (AMRX) Gets a Buy From Barclays
Strong Growth Ahead: Buy Rating for Amneal Pharmaceuticals Amidst Promising Product Launches and Financial Performance
Barclays Remains a Buy on Amneal Pharmaceuticals (AMRX)
Teva Upgraded to Overweight at Piper Sandler on Multiple Expansion
Amneal Pharmaceuticals Analyst Ratings
Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Veeva Systems (VEEV) and Amneal Pharmaceuticals (AMRX)
Piper Sandler Sticks to Its Buy Rating for Amneal Pharmaceuticals (AMRX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Amneal Pharmaceuticals (AMRX) and Hims & Hers Health (HIMS)
No Data